Podcast: Breast Cancer Dialogues

Clinical conversations in HR-positive, HER2-negative breast cancer

How can we make sure our patients with hormone receptor–positive (HR-positive), human epidermal growth factor receptor 2–negative (HER2-negative) breast cancer receive the highest standard of care as therapeutic choices expand? Join host Azadeh Nasrazadani and leading experts as they share clinical insights and forward-thinking strategies for implementing patient-centric care.

Stay tuned to Breast Cancer Dialogues for further expert-led discussions on improving patient outcomes in HR-positive, HER2-negative breast cancer care and innovation.

The views and opinions expressed in this podcast are those of the speakers and do not necessarily reflect those of the sponsor or affiliated organizations.

Leading the charge: New horizons in HR-positive, HER2-negative metastatic breast cancer

Episode 5. “It’s great if a study reaches statistical significance, but does that translate into clinical significance for our patients?” In the final episode of Breast Cancer Dialogues, Azadeh Nasrazadani and Filipa Lynce unpack how emerging treatment strategies are being investigated in ongoing clinical trials to shape the future of HR-positive, HER2-negative metastatic breast cancer.

What is the current burden of treatment in HR-positive, HER2-negative metastatic breast cancer?

Episode 4. “It’s already an emotional rollercoaster for our patients, with many complicated emotions — including guilt, anger, and fear.” Azadeh Nasrazadani and Karen Gelmon discuss the psychological, financial, and mental burden of treatment for HR-positive, HER2-negative metastatic breast cancer, while highlighting approaches to support patient-centric decision-making and the role of clinical trials.

Targeted approaches: Evolving HR-positive, HER2-negative therapies

Episode 3. How are targeted therapies reshaping care in HR-positive, HER2-negative metastatic breast cancer? Filipa Lynce joins Azadeh Nasrazadani to unpack sequencing strategies and resistance mechanisms in this rapidly evolving treatment landscape.

HR-positive, HER2-negative metastatic breast cancer treatment: Where are we now?

Episode 2. What are the key considerations when making treatment decisions for metastatic breast cancer? Azadeh Nasrazadani welcomes Peter Fasching to discuss the current treatment landscape, how genetic testing and quality-of-life considerations guide treatment sequencing and use of combination therapies, and their hopes for the future.

Innovations in HR-positive, HER2-negative early breast cancer: Deep dive into modern therapies

Episode 1. With new approvals around the corner, how do we stay ahead in early breast cancer care? Peter Fasching and Azadeh Nasrazadani discuss the evolving treatment landscape of HR-positive, HER2-negative early breast cancer, including the impact of CDK4/6 and PARP inhibitors on the treatment landscape, and when de-escalation strategies might be considered.

Meet the experts

Azadeh Nasrazadani, MD, PhD

Azadeh Nasrazadani is an Assistant Professor of Breast Medical Oncology at MD Anderson Cancer Center in Houston, Texas, USA. She has expertise in managing a variety of breast malignancies, notably including inflammatory breast cancer, invasive lobular carcinoma, and mixed invasive ductal lobular carcinoma. She also has extensive experience in basic science and translational research, with her doctoral dissertation completed on the role of c-Jun N-terminal kinases in advanced breast cancer.

Disclosures: Consulting fees from AstraZeneca and Novartis.

Peter Fasching, MD

Peter Fasching is Associate Professor of Gynecology and Obstetrics and Translational Medicine at the Friedrich-Alexander University Erlangen-Nuremberg and the National Center for Tumor Diseases WERA in Erlangen, Germany. His research interests include cancer prevention, target discovery, big data, and digital medicine.

Disclosures: Personal fees and/or grants from Agendia, AstraZeneca, Biontech, Cepheid, Daiichi Sankyo, Eisai, Gilead Sciences, Guardant Health, Lilly, Menarini Group, Merck Sharp & Dohme, Mylan, Novartis, Pfizer, Roche, Seagen, and Veracyte.

Filipa Lynce, MD

Filipa Lynce is a medical oncologist and clinical investigator at Dana-Farber Cancer Institute, and an Assistant Professor at Harvard Medical School, Boston, Massachusetts, USA. Her research portfolio includes inflammatory and triple-negative breast cancers, BRCA-mutated disease, and the exploration of innovative therapeutic modalities in breast cancer care.

Disclosures: Consulting and advisory boards for AstraZeneca, Daiichi Sankyo, and Pfizer. Institutional research funding from AstraZeneca, Gilead, Ideaya, Incyte, Merck, and Zentalis.

Karen Gelmon, MD, FRCPC

Karen Gelmon is a Professor of Medicine at the University of British Columbia and a Medical Oncologist at the British Columbia Cancer Agency, Vancouver, Canada. Her career reflects a deep engagement in teaching and public education, supported by a robust portfolio of published work.

Disclosures: Fees for advisory board participation from AstraZeneca, Canadian Breast Cancer Network, Celcuity, City of Hope, Daiichi Sankyo, Gilead, Merck, Novartis, Pfizer, Real Alliance, and Rethink Breast Cancer.